This new lateral flow finger prick sample test could be used to rapidly identify high-risk patients in the ER or at the bedside, thereby greatly expanding the potential market beyond centralized lab testing. It also has strong potential in countries worldwide with less developed centralized laboratory infrastructure.
Dr Andrew Retter, Critical Care Lead and Medical Consultant, Volition, said: “This is a huge step forward toward our goal of making Nu.Q® NETs an easily accessible, cost-effective, minimally invasive test.
“We measured H3.1 nucleosomes in critically ill patients with sepsis, comparing a finger-prick sample read on a lateral flow device with our CE-marked laboratory assay on plasma. The two tracked closely, with a Spearman correlation of 0.85 and a Pearson correlation of 0.881.